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As COVID-19 spreads all around the world, it 
indicates various side effects and complications. 
Currently, we know that, this disease can affect 
other organs like brain. The growing number of 
neurological complications from this disease 
suggests that, the coronavirus is a neurotropic 
virus, and this neurotropicity has been attributed 
to the expression and presence of receptors of 
angiotensin-converting enzyme 2 (ACE2) in 
central nervous system (CNS) (1-3). Unlike ACE 
itself, ACE2 converts angiotensin 2 to 1, and is 
present in lung alveolar epithelial cells. In this 
regard, the coronavirus is likely to use ACE2 as a 
receptor to enter and infect human cells (4). The 
virus causes disease in some other areas such as 
pancreas and colon with the same mechanism as 
that of ACE2 receptor (5, 6). Moreover, the high 
presence of the corresponding receptor in the CNS 
has increased the likelihood of neurological 
involvement in this virus (7). The binding of the 
virus to this receptor (Figure 1), which is present 
in different areas of the brain such as the glial 
cells, neurons and astrocytes spreads the virus to 
the CNS and this induces a variety of neurological 
symptoms (8). One of the most important areas of 
the brain that causes high expressions of ACE and 
ACE2, angiotensinogen, and angiotensin II 
secretion in the CNS, is perivascular astrocytes (9). 
Neuromyelitis optica spectrum disorder (NMOSD) 
is an astrocytopathy in which a high rate of 
astrocyte destruction occurs (10). Some studies 
have also shown that, these perivascular 
astrocytes are largely eliminated in multiple 
sclerosis (MS), especially at chronic stages (9). This 
destruction could justify the studies, which have 
demonstrated the low levels of ACE2 in the 
cerebrospinal fluid of these patients. Matsushita et 
al. revealed that, angiotensin II, ACE, and ACE2 
levels were lower in the cerebrospinal fluid of the 
patients with seropositive NMOSD compared to 
healthy individuals. Accordingly, the same was 
true for ACE2 levels in MS patients (9). Another 
study confirmed the low level of ACE2 
concentration in the cerebrospinal fluid of the 
patients with MS (11). The destruction of astrocytes 
and low level of ACE2 concentration could 
theoretically predict the ACE2 receptor deficiency 
which might reduce the chance of entering the 
virus into the CNS, and consequently, decrease the 
neurological complications. This may suggest that, 
neurological complications are less likely to occur 
in the patients with NMOSD and MS in case of 
developing COVID-19. However, as with all 
diseases, it is not possible to simply predict the 
lower degree of neurological complications in 
these patients on the basis of one factor such as a 
lower expression of ACE2 in these patients. 
Thereafter, further investigations are required to 
shed light on how MS and NMOSD patients 
develop infectious diseases related to the CNS.  
 
Figure 1: Interaction between Coronavirus and astrocytes 
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